TNF antibodies beat them all in Biologics Sales 2008
The Business Intelligence firm La Merie S.L. reported that anti-TNF antibodies were the best selling class of biologics in 2008 with total sales of US$ 16.4 bln. The most successful biologic brand in 2008 was the anti-TNF fusion protein Enbrel (etanercept) with sales of US$ 6.4 bln; the biologic with the strongest growth in 2008 was the anti-TNF antibody adalimumab from Abbott (+ US$ 1.5 bln / + 48 % vs 2007).
Erythropoietins fell down to position 4 with 2008 sales of US$ 10 bln, superseded by the class of anti-cancer antibodies (US$ 15.6 bln) and insulin products (US$ 10.9 bln) due to the continuing success of insulin analogs. The 13 major classes of biologics together posted 2008 sales of US$ 80.6 bln of which 43.4 % originated from antibody sales. The second cluster of successful classes of biologics consisted of interferon beta (US$ 5.4 bln), G-CSF (US$ 5.2 bln) and recombinant coagulation factors (US$ 4.9 bln). 2008 sales of enzyme replacement therapies recorded a strong growth from US$ 2.3 bln in 2007 to US$ 2.8 bln in 2008. These results and more were found in an elaboration prepared by La Merie Business Intelligence and published in a complimentary report. The document entitled “TOP 20 Biologics 2008” can be acquired as a free download at La Merie’s News Center.
The “TOP 20 Biologics 2008” report presents in tabular format 2008 sales figures of the TOP 20 selling single biologic products, of the 13 top-selling classes of recombinant biologicals, i.e. proteins and antibodies (excluding vaccines and peptides), and in detail the sales figures of the individual products of the 13 top selling classes of biologics plus selected other antibodies and proteins and successful peptide drugs. In addition, information is provided on brand and generic names, target, class of compound, originator and licensee companies, product category and major indications.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
